Conference abstractPublished 7 Jun 2017
Drug design via a scaffold hopping strategy: Case studies on discovery of clinical candidates H3 receptor antagonist and β-tryptase inhibitor
Sanofi, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Scaffold hopping is a technique that generates compounds containing a topologically different scaffold from the parent compound, but with similar or improved activity and other properties. This can be done intellectually by medicinal chemists or by computational algorithm. The technique is based on topological pharmacophore models developed from SAR of the current lead. In scaffold hopping, medicinal chemist’s insights into pharmacophore and SAR are crucial in this iterative process. Scaffold hopping can be used to generate new chemical entity; overcome patent or other limitations for the current leads; generate differentiated series of chemical matters. Common approaches include heterocycle replacements, bonds formation and cleavage, and topology-based hopping. This presentation will describe medicinal chemistry of H3 receptor antagonist and tryptase inhibitor programs via using scaffold hopping strategy to generate multi-genesis of chemical leads. Through optimization of the leads, clinical candidates were identified. The profile of the candidates and in vivo effects in disease animal models will also be briefly discussed. Recent Publications (minimum 5) Sun H, Tawa G, Wallqvist A (2012) Classification of scaffold-hopping approaches. Drug Discovery Today 17: 310-324 Hu Y, Stumpfe D, Bajorath J (2016) Recent Advances in Scaffold Hopping. J. Med. Chem. Gao Z, Hurst WJ, Hall D, Hartung R, Reynolds W, Kang J, Nagorny R, Hendrix JA, George PG (2015) Design and synthesis of a novel series of histamine H3 receptor antagonists through a scaffold hopping strategy. Bioorganic & Medicinal Chemistry. 23: 429–438 Gao Z, Hurst WJ, et al., (2013) Synthesis, characterization, and biological assessment of the four stereoisomers of the H3 receptor antagonist 5-fluoro-2-methyl-N-[2-methyl-4-(2-methyl[1,3′]bipyrrolidinyl-1′-yl) phenyl] benzamide. Bioorganic & Medicinal Chemistry Letters. 23:4044–4047. Gao Z, Hurst WJ, et al., (2013) Identification and profiling of 3,5-dimethyl-isoxazole-4-carboxylic acid [2-methyl-4-((2S,3’S)-2-methyl-[1,30]bipyrrolidinyl-10-yl)phenyl] amide as histamine H3 receptor antagonist for the treatment of depression. Bioorganic & Medicinal Chemistry Letters. 23:6269–6273. Gao Z, Hurst WJ, et al., (2013) Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep–wake disorders. Bioorganic & Medicinal Chemistry Letters. 23:6141–6145.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Zhongli Gao”